Real-life use of isavuconazole in Spanish children and adolescents.

ABSTRACT:

Background and objectives

Isavuconazole (ISA) has been recently approved for the treatment of invasive aspergillosis and mucormycosis in patients aged >1 year. Prior to this approval, it was used in paediatric patients under compassionate use. The objective of this study is to describe the experience with ISA use in children.

Patients and methods

A descriptive, retrospective, multicentre study conducted in nine Spanish hospitals, including patients aged ≤18 years who received ≥7 days of ISA between 2018 and 2023. Therapeutic drug monitoring (TDM) was performed with pre-dose [trough concentration (Ctrough)] levels measured according to local protocols. A therapeutic range of 2.5-5 mg/L was used for analysis.

Results

A total of 107 patients (median age: 11 years, 56% ma

SUBMITTER: Mendoza-Palomar N 

PROVIDER: S-EPMC12802926 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature